Bortezomib is indicated for the treatment of multiple myeloma, a type of blood cancer. In cycles 59, velcade is given once weekly days 1, 8, 22, and 29. Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered. In cycles 59, velcade is administered once weekly days 1, 8, 22 and 29. Bortezomib, sold under the brand name velcade among others, is an anticancer medication used to treat multiple myeloma and mantle cell lymphoma. The level of renal function below which the dose of a drug must be reduced depends largely on the extent of renal metabolism and elimination, and on the drugs toxicity. It is currently approved for the treatment of myeloma in the relapsed setting post transplant or as a second line treatment in. Monoclonal gammopathy of renal significance mgrs is defined by the causal relationship between a small bcell clone and renal disease, usually through deposition of the secreted monoclonal immunoglobulin mig or a fragment thereof. If several bortezomib doses in consecutive cycles are withheld due to toxicity, the bortezomib dose should be reduced by 1 dose level from 1. The renal drug handbook the st georges hospital, adult critical. Bortezomib for induction therapy in multiple myeloma. Bortezomib solution, reconstituted recon soln webmd.
It has been studied in a wide range of people, including those with renal impairment and diabetes. Velcade bortezomib dosing, indications, interactions. Velcade bortezomib is administered as a 35 second bolus iv injection in combination with oral melphalan and oral prednisone for nine 6week treatment cycles as shown in table 1. Light chaininduced acute renal failure can be reversed by. The phase 2 international retrieve trial showed a 38. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Velcade may be administered intravenously at a concentration of 1 mgml, or subcutaneously at a concentration of 2. It is approved by the fda for the treatment of multiple myeloma and mantle cell lymphoma. Patients and methods in all, 827 eligible patients with newly diagnosed symptomatic mm were randomly assigned to receive induction therapy with vincristine, doxorubicin, and dexamethasone vad or bortezomib, doxorubicin, and dexamethasone pad. It is a first in class inhibitor of the 20s segment of the proteasome, the cellular component that regulates the degradation of many cell cycle. If your institution subscribes to this resource, and you dont have a myaccess profile, please contact your librarys reference desk for information on how to. In the setting of acute renal injury, here are a couple of criteria to look at and this gets to the idea of attribution of renal dysfunction in patients with myeloma.
Since the growth of normal body cells may also be affected by bortezomib. Bortezomib should be withheld at the onset of any grade 3 nonhematologic or grade 4 toxicities excluding neuropathy. Bortezomib velcade in the treatment of multiple myeloma. Velcade belongs to a class of medicines called proteasome inhibitors. It was submitted to dtp for screening along with 18 analogs in 1995. A novel classification of ckd, based on crcl, has been recently produced table 2.
Renal impairment is a common complication of multiple myeloma mm. In cycles 14, velcade is administered twice weekly days 1, 4, 8, 11, 22, 25, 29 and 32. Authorization of 6 months may be granted for members prescribed velcade for the treatment of multicentric astlemans disease and velcade will be used with or without rituximab as subsequent therapy for disease that has progressed following treatment of relapsed, refractory, or. The standard of care for patients with myeloma and renal impairment are velcade. If highcutoff hemodialysis is not available, plasma exchange may be beneficial. Guidelines for chemotherapy dosage adjustment hematology. The rifle criteria, which are risk, injury, failure, loss, and endstage kidney disease, need to be considered for attribution of renal injury in patients with myeloma. Velcade therapy should be withheld until symptoms of the toxicity have resolved to grade 2 or better. Bortezomib injection is used to treat multiple myeloma blood plasma cell cancer in patients with or without a previous history of treatment, and mantle cell lymphoma bortezomib is an antineoplastic agent cancer medicine. Multiple myeloma and renal or kidney failure the imf. Zovirax acyclovir dosing, indications, interactions.
Renal drug handbook capd, hd, hdfhigh flux 50% dose. Then, velcade may be reinitiated with one dose level reduction from 1. Purpose we investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma mm. Bortezomib is a reversible inhibitor of the 26s proteasome, a protein complex that degrades. If platelet counts dosing day other than day 1 of each cycle velcade therapy should be withheld. If prolonged grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle, consider reducing melphalan dose by 25% in the next cycle. Dosing of bortezomib is similar regardless of the route of application, it does not require renal or hepatic dosing adjustments, and the drug is no longer detectable within 30 minutes of injection. Begin treatment at the last tolerated bortezomib dose, iv or subcutaneous, on days 1, 4, 8, and 11, either as a single agent or in combination with dexamethasone, every 3 weeks for a maximum of 8 cycles.
Dosage adjustment for cytotoxics in renal impairment. By inhibiting proteasomes multienzyme complexes present in all cells, bortezomib interferes with the cell cycle leading to cell death. Patients and methods sixtyeight patients with light chaininduced acute renal failure and glomerular filtration rate gfr less than 50 mlmin received bortezomib 1. Uclh dosage adjustment for cytotoxics in renal impairment version 3 updated january2009 page 3 of 24 drug pharmacokinetics available information recommendation arsenic trioxide arsenic is stored mainly in liver, kidney, heart, lung, hair and nails. Bortezomib with highdose dexamethasone is considered as the. Normal dosage 200 mg q4hr or 400 mg q12hr and crcl dosing schedule to accommodate noncandidates for highdose chemotherapy with autologous stem cell transplantation an often frail patient population.
The formation of donorspecific antibodies dsa and ongoing antibodymediated rejection amr processes may critically contribute to late graft loss. Velcade dose modification calculator free downloads and. Prescribing information and velcade reimbursement assistance program vrap application. This includes multiple myeloma in those who have and have not previously received treatment. With the exception of immunoglobulin light chain al amyloidosis, few. Velcade bortezomib dose, indications, adverse effects. For patients who required velcade dose reductions during induction, the last administered mgm2 dose of velcade will be the starting dose for maintenance, given on days 1 and 15. The acute renal failure that can complicate myeloma can affect survival. Adult drugs analgesics antihypertensive and cardiovascular agents antimicrobial agents miscellaneous agents sedatives, hypnotics, and other drugs used in. Then, bortezomib may be reinitiated with one dose level reduction from 1. Velcade can cause damage to the nerves, a condition called peripheral neuropathy.
Rasburicase fasturtec is a novel uricolytic agent that catalyzes the. Trivalent forms of arsenic are methylated in humans and mostly excreted in urine. Renal improvement in myeloma with bortezomib plus plasma. The company believes that when other additional relevant factors are considered i. The approved retreatment snda consisted of a phase 2 study and other supportive data. Velcade can lead to the formation of blood clots in small blood vessels. Velcade dosing for the firsttime treatment of multiple myeloma when used to treat multiple myeloma in people who have not been previously treated, velcade is given in combination with two medications that are taken by mouth. In addition, based on crcl, a novel classification of chronic kidney disease has. Bortezomib velcade, millennium pharmaceuticals inc. Withhold velcade therapy until symptoms of the toxicity have resolved to grade 2 or better.
However, appropriate treatment for late amr has not yet. Velcade bortezomib is an antineoplastic anticancer agent used to treat multiple myeloma and mantle cell lymphoma, and is sometimes given after other cancer medications have been tried without successful treatment. Bortezomib reversibly inhibits the chymotryptic activity of the 20s subunit of the proteasome and inhibits proliferation and induces apoptosis in mm cell lines and patient tumor cells 121. For velcaderelated neuropathic pain andor peripheral neuropathy, hold or modify velcade as outlined in table 5. Bortezomib velcade, millennium pharmaceuticals, cambridge, ma. Tell your doctor if you have ever had an unusual or allergic reaction to bortezomib before taking bortezomib. If the platelet count is less than or equal to 30 x 109l or anc less than or equal to 0. Both of these two patients had a peak mfi greater than 10,000. Bortezomib, a proteasome inhibitor approved by the fda, is a highly active agent for the treatment of mm. Get emergency medical help if you have signs of an allergic reaction. How to use bortezomib solution, reconstituted recon soln this medication is given by injection into a vein or under the skin by a health care professional.
Despite major advances in transplant medicine, improvements in longterm kidney allograft survival have not been commensurate with those observed shortly after transplantation. The impact of bortezomib in renal transplantation volume 3 issue 1 2016 1alphabiocom, usa. Velcade information, side effects, warnings and recalls. You may feel muscle weakness, tingling, burning, pain, and loss of feeling in your hands and feet, any of which can be severe. The information on dosage adjustments in renal impairment given in this book is based on. A study comparing daratumumab, velcade bortezomib, lenalidomide, and dexamethasone dvrd with velcade, lenalidomide, and dexamethasone vrd in participants with untreated multiple myeloma and for whom hematopoietic stem cell transplant is not planned as initial therapy. Bortezomib is given by a doctor or nurse in a medical office or clinic. Renal impairment in patients with multiple myeloma. Call your doctor right away if you have a severe headache, buzzing in your ears, vision problems, weakness, confusion, thinking problems, or a seizure. The combination of bortezomib and plasma exchange to remove light chains from the circulation can have a beneficial effect o. Welcome to the fifth edition of the renal drug handbook. The use of bortezomib with plasmapheresis was successful in decreasing antibody levels to under mfi within a median time of 24 days from treatment initiation in all but two patients. The introduction of bortezomib, a novel firstinclass proteasome inhibitor, has been a major break through in the treatment of multiple myeloma. How i treat monoclonal gammopathy of renal significance.
Velcade is for intravenous or subcutaneous use only. Tell your doctor if you develop pinpointsized purple dots petechiae, larger bruises, or you see blood in your urine. Bortezomib comes as a solution liquid to inject into a vein or subcutaneously under the skin. Velcade has been studied in many important clinical trials. It is a clear liquid that is injected into a vein or under the skin. Pediatric drugs analgesics antihypertensive and cardiovascular agents antimicrobial agents miscellaneous agents sedatives, hypnotics, and other drugs used in psychiatry. Dosage modification bortezomib, melphalan, and prednisone regimen. Your dosing schedule will depend on the condition that you have, the other medications you are using, and how well your body responds to.
1253 450 903 1220 1571 26 719 1238 178 225 719 1527 995 201 1480 1474 951 959 1580 808 1612 514 245 58 1586 191 1072 1315 722 1001 607 952 262 480 629 1033 450 916 1413